Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas. 1998

K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
CRC Human Cancer Genetics Research Group, Addenbrooke's Hospital, Cambridge, UK.

Female transgenic mice lacking a functional c-mos proto-oncogene develop ovarian teratomas, indicating that c-mos may behave as a tumour-suppressor gene for this type of tumour. We have analysed the entire coding region of the c-MOS gene in a series of human ovarian teratomas to determine whether there are any cancer-causing alterations. DNA from twenty teratomas was analysed by single-strand conformational analysis (SSCA) and heteroduplex analysis (HA) to screen for somatic and germline mutations. In nine of these tumours the entire gene was also sequenced. A previously reported polymorphism and a single new sequence variant were identified, neither of which we would predict to be disease-causing alterations. These results suggest that mutations in the coding region of the c-MOS gene do not play a significant role in the genesis of human ovarian teratomas.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D013724 Teratoma A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642) Dysembryoma,Teratoid Tumor,Teratoma, Cystic,Teratoma, Mature,Teratoma, Benign,Teratoma, Immature,Teratoma, Malignant,Benign Teratoma,Benign Teratomas,Dysembryomas,Immature Teratoma,Immature Teratomas,Malignant Teratoma,Malignant Teratomas,Teratoid Tumors,Teratomas,Teratomas, Benign,Teratomas, Immature,Teratomas, Malignant,Tumor, Teratoid,Tumors, Teratoid
D016258 Genes, mos Retrovirus-associated DNA sequences (mos) originally isolated from the Moloney murine sarcoma virus (Mo-MSV). The proto-oncogene mos (c-mos) codes for a protein which is a member of the serine kinase family. There is no evidence as yet that human c-mos can become transformed or has a role in human cancer. However, in mice, activation can occur when the retrovirus-like intracisternal A-particle inserts itself near the c-mos sequence. The human c-mos gene is located at 8q22 on the long arm of chromosome 8. c-mos Genes,mos Genes,v-mos Genes,c-mos Proto-Oncogenes,mos Oncogenes,mos Proto-Oncogenes,v-mos Oncogenes,Gene, c-mos,Gene, mos,Gene, v-mos,Genes, c-mos,Genes, v-mos,Oncogene, mos,Oncogene, v-mos,Oncogenes, mos,Oncogenes, v-mos,Proto-Oncogene, c-mos,Proto-Oncogene, mos,Proto-Oncogenes, c-mos,Proto-Oncogenes, mos,c mos Genes,c mos Proto Oncogenes,c-mos Gene,c-mos Proto-Oncogene,mos Gene,mos Oncogene,mos Proto Oncogenes,mos Proto-Oncogene,v mos Genes,v mos Oncogenes,v-mos Gene,v-mos Oncogene
D018807 Polymorphism, Single-Stranded Conformational Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels. SSCP,Single-Stranded Conformational Polymorphism,Conformational Polymorphism, Single-Stranded,Conformational Polymorphisms, Single-Stranded,Polymorphism, Single Stranded Conformational,Polymorphisms, Single-Stranded Conformational,Single Stranded Conformational Polymorphism,Single-Stranded Conformational Polymorphisms

Related Publications

K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
September 1985, The EMBO journal,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
June 1993, Oncogene,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
January 1990, Ciba Foundation symposium,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
March 1994, Fertility and sterility,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
June 1995, Japanese journal of cancer research : Gann,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
January 1985, Nature,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
October 1986, Biochemical and biophysical research communications,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
August 1996, British journal of cancer,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
February 1988, Molecular and cellular biology,
K A de Foy, and S A Gayther, and W H Colledge, and S Crockett, and I V Scott, and M J Evans, and B A Ponder
January 1991, Anticancer research,
Copied contents to your clipboard!